NO3049208T3 - - Google Patents

Info

Publication number
NO3049208T3
NO3049208T3 NO14741534A NO14741534A NO3049208T3 NO 3049208 T3 NO3049208 T3 NO 3049208T3 NO 14741534 A NO14741534 A NO 14741534A NO 14741534 A NO14741534 A NO 14741534A NO 3049208 T3 NO3049208 T3 NO 3049208T3
Authority
NO
Norway
Application number
NO14741534A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3049208(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3049208T3 publication Critical patent/NO3049208T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO14741534A 2012-12-14 2014-06-30 NO3049208T3 (https=)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
NO3049208T3 true NO3049208T3 (https=) 2018-04-14

Family

ID=50934967

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14741534A NO3049208T3 (https=) 2012-12-14 2014-06-30

Country Status (11)

Country Link
US (3) US9822347B2 (https=)
EP (2) EP3326622B1 (https=)
JP (2) JP6345690B2 (https=)
AU (3) AU2013359179B2 (https=)
CA (1) CA2894539C (https=)
DK (2) DK3326622T3 (https=)
ES (2) ES2665323T7 (https=)
FI (1) FI2931265T6 (https=)
NO (1) NO3049208T3 (https=)
PT (2) PT3326622T (https=)
WO (1) WO2014093690A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2525824T (pt) * 2010-01-22 2017-07-13 Univ Leland Stanford Junior Inibição da sinalização de axl em terapêutica antimetastática
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
CA2894539C (en) 2012-12-14 2021-09-28 The Board Of Trustees Of The Leland Stanford Junior University Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
US10876176B2 (en) 2014-12-18 2020-12-29 Aravive Biologics, Inc. Antifibrotic activity of GAS6 inhibitor
EP3703731A4 (en) * 2017-11-04 2021-07-21 Aravive Biologics, Inc. METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS
EP4398937A4 (en) * 2021-09-11 2025-07-09 Aravive Inc METHODS FOR TREATING LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA USING AXL DECOY RECEPTORS AS FIRST-LINE THERAPY

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030022293A1 (en) 1997-09-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2004108748A2 (en) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
WO2004092735A2 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
JP2008522162A (ja) 2004-11-24 2008-06-26 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド Ｍｅｒの診断用および治療用の作用薬
CA2607133A1 (en) 2005-05-02 2006-11-09 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
CA2692320A1 (en) 2007-07-02 2009-01-08 Wyeth Methods of treating bone disorders with modulators of axl
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
WO2010070047A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
CA2759836A1 (en) * 2009-05-11 2010-11-18 U3 Pharma Gmbh Humanized axl antibodies
PT2525824T (pt) * 2010-01-22 2017-07-13 Univ Leland Stanford Junior Inibição da sinalização de axl em terapêutica antimetastática
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US10844106B2 (en) 2010-11-08 2020-11-24 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
US9879061B2 (en) * 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
WO2014093707A1 (en) 2012-12-14 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in primary tumor therapy
CA2894539C (en) 2012-12-14 2021-09-28 The Board Of Trustees Of The Leland Stanford Junior University Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
US20160266136A1 (en) * 2013-08-30 2016-09-15 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
US10137173B2 (en) * 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
US10876176B2 (en) * 2014-12-18 2020-12-29 Aravive Biologics, Inc. Antifibrotic activity of GAS6 inhibitor

Also Published As

Publication number Publication date
JP6832887B2 (ja) 2021-02-24
ES2862335T3 (es) 2021-10-07
AU2019210662A1 (en) 2019-08-22
US20220220458A1 (en) 2022-07-14
ES2665323T3 (es) 2018-04-25
US20150315553A1 (en) 2015-11-05
FI2931265T6 (fi) 2023-05-23
DK3326622T3 (da) 2021-04-06
EP2931265A1 (en) 2015-10-21
AU2013359179B2 (en) 2017-10-05
WO2014093690A1 (en) 2014-06-19
AU2013359179A1 (en) 2015-07-02
AU2019210662B2 (en) 2021-07-01
EP2931265B3 (en) 2023-04-05
HK1256071A1 (en) 2019-09-13
EP2931265A4 (en) 2016-08-31
EP3326622A1 (en) 2018-05-30
EP3326622B1 (en) 2021-01-20
US11136563B2 (en) 2021-10-05
ES2665323T7 (es) 2023-06-15
AU2017272193A1 (en) 2017-12-21
CA2894539C (en) 2021-09-28
DK2931265T3 (en) 2018-04-16
JP2016510309A (ja) 2016-04-07
US9822347B2 (en) 2017-11-21
JP6345690B2 (ja) 2018-06-20
US20180030422A1 (en) 2018-02-01
CA2894539A1 (en) 2014-06-19
DK2931265T6 (da) 2023-05-01
JP2018154641A (ja) 2018-10-04
PT2931265T (pt) 2018-04-16
PT3326622T (pt) 2021-04-07
EP2931265B1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
BR112014017635A2 (https=)
BR112014017625A2 (https=)
BR112014017659A2 (https=)
BR112014017646A2 (https=)
BR112014018648A2 (https=)
BR112014017638A2 (https=)
AR092201A1 (https=)
BR112013027865A2 (https=)
BR112014017644A2 (https=)
BR112014017634A2 (https=)
BR112014017588A2 (https=)
BR112014017647A2 (https=)
BR112014013184A8 (https=)
BR112014017618A2 (https=)
BR112014017627A2 (https=)
BR112014017652A2 (https=)
BR112014017630A2 (https=)
BR112014017621A2 (https=)
BR112014017631A2 (https=)
BR112014017641A2 (https=)
BR112014017671A2 (https=)
BR112014017589A2 (https=)
NO3049208T3 (https=)
BR112014017636A2 (https=)
BR112014017667A2 (https=)